Louisiana State Employees Retirement System Invests $790,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Louisiana State Employees Retirement System acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 27,300 shares of the specialty pharmaceutical company's stock, valued at approximately $790,000.

A number of other large investors also recently bought and sold shares of SUPN. China Universal Asset Management Co. Ltd. grew its holdings in Supernus Pharmaceuticals by 96.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company's stock worth $39,000 after purchasing an additional 687 shares during the last quarter. Covestor Ltd grew its holdings in Supernus Pharmaceuticals by 115.0% in the third quarter. Covestor Ltd now owns 2,350 shares of the specialty pharmaceutical company's stock worth $65,000 after purchasing an additional 1,257 shares during the last quarter. Envestnet Portfolio Solutions Inc. purchased a new position in Supernus Pharmaceuticals in the third quarter worth $262,000. Profund Advisors LLC grew its holdings in shares of Supernus Pharmaceuticals by 17.7% during the third quarter. Profund Advisors LLC now owns 9,660 shares of the specialty pharmaceutical company's stock valued at $266,000 after buying an additional 1,454 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Supernus Pharmaceuticals by 28.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,949 shares of the specialty pharmaceutical company's stock valued at $274,000 after buying an additional 2,203 shares during the last quarter.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN traded up $0.76 during trading on Friday, reaching $30.07. 330,640 shares of the company's stock traded hands, compared to its average volume of 328,166. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $21.99 and a fifty-two week high of $38.09. The company has a 50-day simple moving average of $31.51 and a 200-day simple moving average of $28.62.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.41 by ($0.39). Supernus Pharmaceuticals had a net margin of 0.22% and a return on equity of 0.14%. The business had revenue of $164.30 million for the quarter, compared to analyst estimates of $155.03 million. During the same quarter last year, the business earned $0.43 earnings per share. Supernus Pharmaceuticals's revenue was down 1.8% on a year-over-year basis. As a group, equities analysts expect that Supernus Pharmaceuticals, Inc. will post 1.16 EPS for the current fiscal year.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 5,000 shares of the firm's stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $30.21, for a total value of $151,050.00. Following the transaction, the vice president now directly owns 8,570 shares of the company's stock, valued at approximately $258,899.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 12,364 shares of the firm's stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $35.31, for a total value of $436,572.84. Following the transaction, the vice president now directly owns 8,570 shares of the company's stock, valued at approximately $302,606.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $30.21, for a total transaction of $151,050.00. Following the completion of the transaction, the vice president now directly owns 8,570 shares in the company, valued at $258,899.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,739 shares of company stock valued at $1,227,433. 8.76% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Piper Sandler dropped their price objective on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an "overweight" rating on the stock in a report on Wednesday, February 28th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.